ALISO VIEJO, Calif., March 27, 2008 (PRIME NEWSWIRE) -- Clarient, Inc. (Nasdaq:CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2007, and certain future expectations in a conference call before the stock market opens on Monday, March 31.
Date: Monday, March 31, 2008 Start Time: 8:00 a.m. EDT Call-in Number: 1-877-356-3962 (International) +706-634-5888 Webcast: www.clarientinc.com/investor Web Replay: For those unable to participate during the live broadcast, the webcast replay will be archived at www.clarientinc.com/investor shortly after the call and will be available for one year. Host: President and CEO Ronald A. Andrews Format: Discussion of fourth quarter 2007 financial results followed by Q&A
About Clarient
Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com
About Safeguard
Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE:SFE) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS), Technology-Enabled Services and Internet-based Businesses, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. www.safeguard.com